Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2014

Open Access 01-02-2014 | Research

New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study

Authors: Hiroyasu Ishikura, Takeshi Nishida, Akira Murai, Yoshihiko Nakamura, Yuhei Irie, Junichi Tanaka, Takehiro Umemura

Published in: Critical Care | Issue 1/2014

Login to get access

Abstract

Introduction

Inflammation and coagulation are closely interrelated pathophysiologic processes in the pathogenesis of sepsis. However, the diagnostic criteria of sepsis and disseminated intravascular coagulation (DIC) are different. This study aimed to define a biomarker panel to predict sepsis-induced DIC in emergency department patients.

Methods

Eighty-two patients who were admitted to the emergency department of a tertiary university hospital were included in this study. The inclusion criteria were as follows: (1) age >18 years; (2) ≥1 systemic inflammatory response syndrome (SIRS) criteria. Patients were excluded if they lacked biomarker data or apparent clinical manifestations. Eleven biomarkers were assayed from blood drawn on ED admission. Receiver operating curve (ROC) analysis including the area under the ROC and multivariable logistic regression were used to identify an optimal combination of biomarkers to create a diagnostic panel. The derived formula for weighting biomarker values was used to determine the severity of sepsis-induced DIC, which was divided into three categories: mild, moderate, and severe. We also investigated the ability of this classification to predict secondary outcome measures of rates of sepsis and DIC, DIC score, acute physiology and chronic health evaluation (APACHE) II score, sequential organ failure score (SOFA) score, and 28-day all-cause mortality.

Results

Among the 11 biomarkers tested, the optimal 2-marker panel comprised presepsin and protein C. The area under the curve for the accuracies of predicting sepsis and DIC from these two biomarkers were 0.913 and 0.880, respectively. When patients were divided according to the severity of sepsis-induced DIC, all secondary outcomes except for mortality were significantly higher depending on the severity (P < .0001). The overall mortality rates of mild, moderate, and severe sepsis-induced DIC were 7.14%, 15.4%, and 28.6%, respectively (P = .0994).

Conclusions

A biomarker panel of presepsin and protein C is predictive of the severity of sepsis-induced DIC in suspected ED patients. These criteria for sepsis-induced DIC are very simple, easy to implement, and can be used in intensive care units as a point-of-care test.
Appendix
Available only for authorised users
Literature
1.
Moore LJ, Moore FA, Todd SR, Jones SL, Turner KL, Bass BL: Sepsis in general surgery: the 2005–2007 national surgical quality improvement program perspective. Arch Surg 2010, 145: 695-700. 10.1001/archsurg.2010.107CrossRefPubMed
2.
3.
Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013, 41: 580-637. 10.1097/CCM.0b013e31827e83afCrossRefPubMed
4.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Crit Care Med 1992, 20: 864-874. 10.1097/00003246-199206000-00025
5.
Ogura H, Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Kushimoto S, Saitoh D, Endo S, Shimazaki S: SIRS-associated coagulopathy and organ dysfunction in critically ill patients with thrombocytopenia. Shock 2007, 28: 411-417. 10.1097/shk.0b013e31804f7844CrossRefPubMed
6.
Gando S, Kameue T, Nanzaki S, Nakanishi Y: Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996, 75: 224-228.PubMed
7.
Range-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273: 117-123. 10.1001/jama.1995.03520260039030CrossRef
8.
Dhainaut JF, Yan SB, Joyce DE, Pettilä V, Basson B, Brandt JT, Sundin DP, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2: 1924-1933. 10.1111/j.1538-7836.2004.00955.xCrossRefPubMed
9.
Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM: Treatments effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4: 90-97.CrossRefPubMed
10.
Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, Martin G, Martin C, Ramsey G, Silva E, Vallet B, Vincent JL, Janes JM, Sarwat S, Williams MD: Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 2009, 37: 222-232. 10.1007/s15010-008-8203-zCrossRefPubMed
11.
Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36: 296-327. 10.1097/01.CCM.0000298158.12101.41CrossRefPubMed
12.
Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34: 344-353. 10.1097/01.CCM.0000194725.48928.3ACrossRefPubMed
13.
14.
Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, Mayumi T, Murata A, Ikeda T, Ishikura H, Ueyama M, Ogura H, Kushimoto S, Saitoh D, Endo S, Shimazaki S: A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med 2006, 34: 625-631.PubMed
15.
Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985, 13: 818-829. 10.1097/00003246-198510000-00009CrossRefPubMed
16.
Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 1998, 26: 1793-1800. 10.1097/00003246-199811000-00016CrossRefPubMed
17.
Kurihara T, Yanagida A, Yokoi H, Koyata A, Matsuya T, Ogawa J, Okamura Y, Miyamoto D: Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal Biochem 2008, 375: 144-146. 10.1016/j.ab.2007.12.030CrossRefPubMed
18.
Okamura Y, Yokoi H: Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta 2011, 412: 2157-2161. 10.1016/j.cca.2011.07.024CrossRefPubMed
19.
Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143: 29-36.CrossRefPubMed
20.
Ulloa L, Tracey KJ: The “cytokine profile”: a code for sepsis. Trends Mol Med 2005, 11: 56-63. 10.1016/j.molmed.2004.12.007CrossRefPubMed
21.
Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K: Epidemiology of severe sepsis occurring in the first 24 hrs in the intensive care unit in England, Wales, and Northern Ireland. Crit Care Med 2003, 31: 2332-2338. 10.1097/01.CCM.0000085141.75513.2BCrossRefPubMed
22.
Peters K, Unger RE, Brunner J, Kirkpatrick CJ: Molecular basis of endothelial dysfunction in sepsis. Cardiovasc Res 2003, 60: 49-57. 10.1016/S0008-6363(03)00397-3CrossRefPubMed
23.
van der Poll T, Levi M: Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol 2012, 10: 632-638. 10.2174/157016112801784549CrossRefPubMed
24.
25.
26.
Zeerleder S, Hack CE, Wuillemin WA: Disseminated intravascular coagulation in sepsis. Chest 2005, 128: 2864-2875. 10.1378/chest.128.4.2864CrossRefPubMed
27.
Wada H, Wakita Y, Nakase T, Shimura M, Hiyoyama K, Nagaya S, Mori Y, Shiku H: Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 1995, 74: 848-852.PubMed
28.
Furusako S, Shirakawa K: Methods for detecting human low molecular weight CD14. United States patent; 2008:US7465547 B2.
29.
Furusako S, Shirakawa K, Hirose J: Soluble CD14 antigen. United States patent; 2009:US7608684 B2.
30.
Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, Takahashi G, Miyata M, Furusako S, Endo S: Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother 2005, 11: 234-238. 10.1007/s10156-005-0400-4CrossRefPubMed
31.
Kojika M, Takahashi G, Matsumoto N, Kikkawa T, Hoshikawa K, Shioya N, Shibata S, Suzuki Y, Aoki H, Shirakawa K, Endo S: Serum levels of soluble CD14 subtype reflect the APACHE II and SOFA Scores. Med Postgrad 2010, 48: 46-50.
32.
Takahashi G, Suzuki Y, Kojika M, Matsumoto N, Shozushima T, Makabe H, Yamada Y, Shioya N, Shibata S, Shirakawa K, Endo S: Evaluation of responses to IVIG therapy in patients with severe sepsis and septic shock by soluble CD14 subtype monitoring. Med Postgrad 2010, 48: 19-24.
33.
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S: Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother 2011, 17: 764-769. 10.1007/s10156-011-0254-xCrossRefPubMed
34.
Mussap M, Noto A, Fravega M, Fanos V: Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011, 24: 12-14.CrossRefPubMed
35.
Endo S, Suzuki Y, Takahashi G, Shozushima T, Ishikura H, Murai A, Nishida T, Irie Y, Miura M, Iguchi H, Fukui Y, Tanaka K, Nojima T, Okamura Y: Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother 2012, 18: 891-897. 10.1007/s10156-012-0435-2CrossRefPubMed
36.
Levi M, van der Poll T, ten Cate H, van Deventer SJ: The cytokine-mediated between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Ivest 1997, 27: 3-9.CrossRef
37.
Farthmann EH, Schoffel U: Principles and limitations of operative management of intaabdominal infections. World J Surg 1990, 14: 210-217. 10.1007/BF01664875CrossRefPubMed
38.
Garcia-Sabrido JM, Talado JM, Christou NV: Treatment of severe inta-abdominal sepsis and/or necrotic foci by an open abdomen approach: zipper and zipper-mesh techniques. Arch Surg 1988, 123: 152-156. 10.1001/archsurg.1988.01400260032002CrossRefPubMed
39.
Bernard GR, Hartman DL, Helterbrand JD, Fisher CJ: Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28-day survival in patients with severe sepsis. Crit Care Med 1999, 27: S33-S35.CrossRef
40.
Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL: Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003, 7: 155-163. 10.1186/cc2167PubMedCentralCrossRefPubMed
41.
Yan SB, Dhainaut JF: Activated protein C versus protein C in severe sepsis. Crit Care Med 2001, 29: S69-S74.CrossRefPubMed
42.
Dhainaut JF, Yan SB, Cariou A, Mira JP: Soluble thrombomodulin, plasma-derived unactivated protein C, and recombinant human activated protein C in sepsis. Crit Care Med 2002, 30: S318-S323. 10.1097/00003246-200205001-00023CrossRefPubMed
43.
Bernard GR, Vincent JL, Laterre PF: Efficiacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699-709. 10.1056/NEJM200103083441001CrossRefPubMed
44.
Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL: Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 2000, 28: 2209-2216.CrossRefPubMed
45.
Marlar RA, Endres BJ, Miler C: Serial studies of protein C and its plasma inhibitor in patients with DIC. Blood 1985, 66: 59-63.PubMed
46.
Jonge E, Levi M, Van der Poll T: Natural anticoagulants in disseminated intravascular coagulation and sepsis. In Yearbook of Intensive Care and Emergency Medicine. Edited by: Vincent JL. Berlin: Springer-Verlag; 2001:348-352.
47.
Macias WL, Nelson DR: Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004, 32: S223-S228. 10.1097/01.CCM.0000126120.49367.ACCrossRefPubMed
48.
Fisher CJ Jr, Yan SB: Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000, 28: S49-S56. 10.1097/00003246-200009001-00011CrossRefPubMed
49.
Macias WL, Derchak PA: Coagulopathy may occur before the clinical diagnosis of organ dysfunction. Crit Care Med 2002, 30: S100.CrossRef
50.
Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, Ohtomo Y, Okamoto K, Kushimoto S, Endo S, Shimazaki S: Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008, 36: 145-150. 10.1097/01.CCM.0000295317.97245.2DCrossRefPubMed
51.
Taylor FB Jr, Toh CH, Hoot WK, Wada H, Levi M: Toward definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86: 1327-1330.PubMed
Metadata
Title
New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study
Authors
Hiroyasu Ishikura
Takeshi Nishida
Akira Murai
Yoshihiko Nakamura
Yuhei Irie
Junichi Tanaka
Takehiro Umemura
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13700

Other articles of this Issue 1/2014

Critical Care 1/2014 Go to the issue

Commentary

Choosing wisely - when to mend a broken heart with ECMO?

Letter

Malignant hyperthermia in the intensive care setting

Research

Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review

Research

Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study

Commentary

Skeletal muscle mass and mortality - but what about functional outcome?

Commentary

Clinical monitoring of peripheral perfusion: there is more to learn